SG55069A1 - Compounds with growth hormone releasing properties - Google Patents

Compounds with growth hormone releasing properties

Info

Publication number
SG55069A1
SG55069A1 SG1996004604A SG1996004604A SG55069A1 SG 55069 A1 SG55069 A1 SG 55069A1 SG 1996004604 A SG1996004604 A SG 1996004604A SG 1996004604 A SG1996004604 A SG 1996004604A SG 55069 A1 SG55069 A1 SG 55069A1
Authority
SG
Singapore
Prior art keywords
growth hormone
compounds
hormone releasing
releasing properties
pct
Prior art date
Application number
SG1996004604A
Other languages
English (en)
Inventor
Nils Langeland Johansen
Jesper Lau
Kjeld Madsen
Behrend Friedrich Lundt
Henning Thogersen
Birgit Sehested Hansen
Bernd Peschke
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK143993A external-priority patent/DK143993D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of SG55069A1 publication Critical patent/SG55069A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG1996004604A 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties SG55069A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK143993A DK143993D0 (de) 1993-12-23 1993-12-23
DK12194 1994-01-28
DK119194 1994-10-14

Publications (1)

Publication Number Publication Date
SG55069A1 true SG55069A1 (en) 1998-12-21

Family

ID=27220421

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004604A SG55069A1 (en) 1993-12-23 1994-12-22 Compounds with growth hormone releasing properties

Country Status (27)

Country Link
US (1) US5767085A (de)
EP (1) EP0736039B1 (de)
JP (1) JP3181918B2 (de)
KR (1) KR100354897B1 (de)
CN (1) CN1052731C (de)
AT (1) ATE197158T1 (de)
AU (1) AU689181B2 (de)
BR (1) BR9408377A (de)
CA (1) CA2179597A1 (de)
CZ (1) CZ293113B6 (de)
DE (1) DE69426206T2 (de)
DK (1) DK0736039T3 (de)
ES (1) ES2153469T3 (de)
FI (1) FI962584A (de)
GR (1) GR3035150T3 (de)
HU (1) HU224345B1 (de)
IL (1) IL112112A (de)
MX (1) MX9500072A (de)
NO (1) NO315561B1 (de)
NZ (1) NZ277486A (de)
PL (1) PL181280B1 (de)
PT (1) PT736039E (de)
RO (1) RO115635B1 (de)
SG (1) SG55069A1 (de)
SK (1) SK281963B6 (de)
UA (1) UA42747C2 (de)
WO (1) WO1995017423A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0730578A4 (de) * 1993-11-24 1997-10-08 Merck & Co Inc Indolyl-gruppen enthaltende verbindungen und deren verwendung zur förderung der freisetzung von wachstumshormonen
IL112111A (en) * 1993-12-23 2000-07-16 Novo Nordisk As Peptides having growth hormone releasing properties and pharmaceutical compositions containing them
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
PL186511B1 (pl) * 1995-01-27 2004-01-30 Novo Nordisk As Nowe związki peptydowe, kompozycje farmaceutycznedo pobudzania uwalniania hormonu wzrostu i zastosowanie tych związków do wytwarzania leku do pobudzania uwalniania hormonu wzrostu
IL122371A0 (en) * 1995-06-22 1998-06-15 Novo Nordisk As Compounds with growth hormone releasing properties
JP3798024B2 (ja) 1995-12-13 2006-07-19 メルク エンド カンパニー インコーポレーテッド 成長ホルモン分泌促進物質レセプターアッセイ
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
GB2308362A (en) * 1995-12-19 1997-06-25 Lilly Industries Ltd Pharmaceutical indole derivatives
EP0869974B1 (de) * 1995-12-22 2009-03-04 Novo Nordisk A/S Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5919777A (en) * 1996-04-24 1999-07-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
EP0907643B1 (de) * 1996-04-24 2003-01-15 Novo Nordisk A/S Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
WO1998008492A1 (en) * 1996-08-29 1998-03-05 Novo Nordisk A/S Transdermal delivery of peptides
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU7906998A (en) 1997-06-20 1999-01-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
DE69921611T2 (de) 1998-01-16 2005-11-03 Novo Nordisk A/S Verbindungen mit wachstumshormon-freisetzenden eigenschaften
US6919315B1 (en) 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
CA2333857A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
EP1112282A4 (de) 1998-08-10 2002-10-31 Merck & Co Inc Rezeptor des wachstumshormon-sekretionsförderers aus dem hund
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
ATE284415T1 (de) 1999-01-06 2004-12-15 Genentech Inc Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i)
KR100699404B1 (ko) 1999-02-18 2007-03-23 가켄 세야쿠 가부시키가이샤 성장 호르몬 분비촉진제로서의 신규 아미드 유도체
JP2003501394A (ja) * 1999-06-04 2003-01-14 ノボ ノルディスク アクティーゼルスカブ 延長された重度の疾患の異化状態の処理のための組成物
DE60133271T2 (de) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
EP1159964B1 (de) 2000-05-31 2009-10-28 Pfizer Products Inc. Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
EA008572B1 (ru) * 2003-05-19 2007-06-29 Уорнер-Ламберт Компани Ллс Твёрдая желатиновая капсула, содержащая оксид титана с контролируемым размером частиц, и способ её получения
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1667521B1 (de) 2003-09-12 2011-12-07 Tercica, Inc. Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
WO2005027913A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
CA2565324A1 (en) * 2004-03-30 2005-10-20 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
US8536120B2 (en) * 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US20100099640A1 (en) 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
EP2225226B1 (de) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Verbindungen und ihre verwending in einem verfahren zur behandlung von krebs
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
UA105657C2 (uk) 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
SG176717A1 (en) * 2009-06-12 2012-01-30 Helsinn Therapeutics Us Inc Ipamorelin diacetate injection and infusion solutions
EP2552915B1 (de) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Verbindungen zur behandlung von hiv
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228156A (en) * 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) * 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) * 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
WO1983002272A1 (en) * 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4803261A (en) * 1986-06-27 1989-02-07 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide
IL98910A0 (en) * 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) * 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
WO1994007519A1 (en) * 1992-09-25 1994-04-14 Smithkline Beecham Corporation Growth hormone releasing peptides
EP0730578A4 (de) * 1993-11-24 1997-10-08 Merck & Co Inc Indolyl-gruppen enthaltende verbindungen und deren verwendung zur förderung der freisetzung von wachstumshormonen

Also Published As

Publication number Publication date
FI962584A0 (fi) 1996-06-20
KR100354897B1 (ko) 2003-01-06
HU9501947D0 (en) 1995-11-28
CZ183496A3 (en) 1997-02-12
GR3035150T3 (en) 2001-04-30
DE69426206D1 (de) 2000-11-30
EP0736039A1 (de) 1996-10-09
DE69426206T2 (de) 2001-05-17
DK0736039T3 (da) 2001-02-12
FI962584A (fi) 1996-06-20
NO962665L (no) 1996-08-23
US5767085A (en) 1998-06-16
CZ293113B6 (cs) 2004-02-18
HUT73497A (en) 1996-08-28
RO115635B1 (ro) 2000-04-28
NO962665D0 (no) 1996-06-21
AU689181B2 (en) 1998-03-26
PL315113A1 (en) 1996-10-14
NZ277486A (en) 1997-03-24
HU224345B1 (hu) 2005-08-29
JPH09507217A (ja) 1997-07-22
IL112112A (en) 2000-06-29
ATE197158T1 (de) 2000-11-15
PT736039E (pt) 2001-04-30
PL181280B1 (pl) 2001-07-31
CN1138335A (zh) 1996-12-18
SK281963B6 (sk) 2001-09-11
UA42747C2 (uk) 2001-11-15
NO315561B1 (no) 2003-09-22
ES2153469T3 (es) 2001-03-01
CN1052731C (zh) 2000-05-24
EP0736039B1 (de) 2000-10-25
MX9500072A (es) 1997-05-31
CA2179597A1 (en) 1995-06-29
SK82096A3 (en) 1997-01-08
BR9408377A (pt) 1997-08-19
IL112112A0 (en) 1995-03-15
JP3181918B2 (ja) 2001-07-03
AU1272495A (en) 1995-07-10
WO1995017423A1 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
SG55069A1 (en) Compounds with growth hormone releasing properties
PL310171A1 (en) Novel imidazopyridines
GB2364304A (en) Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
IL114794A0 (en) Peptidic compounds analogous to distramycin process for their preparation and their use
HK1002017A1 (en) Lyospheres comprising gonadotropin
ZA945817B (en) Tropyl 7-azaindol-3-ylcarboxyamides
GB9126725D0 (en) Process
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
AU4706293A (en) Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine
MX9710377A (es) Compuestos con propiedades de liberacion de la hormona de crecimiento.
GB9410207D0 (en) Process
ZA939227B (en) Novel triazoloquinazolines,their preparation and use
TW288005B (de)
NO950114L (no) Amylin-antagonister og agonister
NZ510253A (en) Neuroprotection
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them
JO1711B1 (en) Therapeutic agents